IN THE NEWS

Alexis Howerton On Starting Up From New Science

Source: Life Science Leader
By Wayne Koberstein, Executive Editor, Life Science Leader magazine

It is not often I meet my interview subject in the elevator on the way to our meeting room. By the time we get to the right floor, Alexis Howerton, the founding CEO of Spruce Biosciences, has recognized me from a photo and introduced herself, and we have already started the conversation. Our meeting was set only a day or so before we both attended this industry event, and I come knowing next to nothing about Spruce or its lead drug candidate, SPR001, now in midstage development for treating congenital adrenal hyperplasia (CAH).

Read More +

 

Rare Disease Report: Spruce Launches CAH Natural History Study

Yesterday, in observance of Rare Disease Day, Spruce Biosciences announced the launch of the CAH Natural History Study, an initiative to advance knowledge and awareness of congenital adrenal hyperplasia (CAH).

Read More +

ALL NEWS

 


 

PRESS RELEASES

Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations

Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company’s lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications

Read More +

 

Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day

Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands

Read More +

ALL PRESS RELEASES

 

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.